AI-Driven Chimeric Animal Inflammation Management System

The original patent addressed the issue of immune response and inflammation in chimeric animals after birth. However, it did not provide a holistic solution for real-time monitoring, personalized treatment, and data management. The present invention solves this problem by synergistically combining AI, IoT, blockchain, and novel biomaterials to create a powerful system for managing inflammation in chimeric animals.

The new claims introduce a synergistic combination of AI, IoT, blockchain, and novel biomaterials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a comprehensive and personalized system for managing inflammation in chimeric animals.

Alternative embodiments could include using different AI algorithms, IoT devices, or blockchain platforms. Variations could involve integrating additional technologies, such as gene editing or nanotechnology, to further enhance the system's capabilities.

The invention has significant commercial potential in the animal health industry, particularly in the fields of xenotransplantation, regenerative medicine, and precision agriculture. The target market includes pharmaceutical companies, research institutions, and animal breeding organizations.